In dialysis patients there is increasing evidence of the
|
|
- Ashlyn Park
- 5 years ago
- Views:
Transcription
1 brain and cerebrospinal fluid of ESRF patients (3,4). Guanidine is a competitive gamma-amino butyric acid (GABA) receptor antagonist and may counteract GABA inhibition of respiratory muscles (4). In this particular case, gabapentin, a novel amino acid derived by the addition of a cyclohexyl group to the chemical backbone of GABA, may have been effective in treating hiccups for two reasons: it increased endogenous GABA-mediated inhibition of inspiratory muscles (3,4), or it reduced calcium influx via inhibition of voltage-operated calcium channels in presynaptic terminals of respiratory muscles. Furthermore, gabapentin also increases the levels of serotonin, an important neurotransmitter for the raphe magnus nucleus in the medulla, the most likely source of GABAergic inhibitory inputs to the hiccup reflex arc (5). Indeed, there are several reports of gabapentin being used for the treatment of intractable hiccups in the setting of cancer or gastrointestinal disorders, but not in ESRF (6 8). Dizziness, somnolence, and peripheral edema are the most frequent side effects of gabapentin. However, in trials where gabapentin was used for treating hiccups (6 8), no side effects were reported. Gabapentin is also advantageous in that it is effective for restless leg syndrome, neuropathic pain, and pruritis in patients with renal failure (9,10). Thus, gabapentin may be useful for ESRF patients with intractable idiopathic hiccups. REFERENCES 668 Andrew M.L. Ong* Chieh Suai Tan Marjorie W.Y. Foo Terence Y.S. Kee Renal Medicine Singapore General Hospital Singapore * andrew.mingliang@gmail.com 1. Alonso-Navarro H, Rubio L, Jimenez-Jimenez FJ. Refractory hiccups: successful treatment with gabapentin. Clin Neuropharmacol 2007; 30: Hansen BJ, Rosenberg J. Persistent postoperative hiccups: a review. Acta Anaesthesiol Scand 1993; 37: Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988; 109: De Deyn PP, D Hooge R, Van Bogaert PP, Marescau B. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int Suppl 2001; 78:S Oshima T, Sakamoto M, Tatsuta H, Arita H. GABAergic inhibition of hiccup-like reflex induced by electrical stimu- lation in medulla of cats. Neurosci Res 1998; 30: Porzio G, Aielli F, Narducci F, Varrassi G, Ricevuto E, Ficorella C, et al. Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J 2003; 116(1182):U Petroianu G, Hein G, Stegmeier-Petroianu A, Bergler W, Rufer R. Gabapentin add-on therapy for idiopathic chronic hiccup (ICH). J Clin Gastroenterol 2000; 30: Hernandez JL, Pajaron M, Garcia-Regata O, Jimenez V, Gonzalez-Macias J, Ramos-Estebanez C. Gabapentin for intractable hiccup. Am J Med 2004; 117: Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritis in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19: Molnar MZ, Novak M, Mucsi I. Management of restless leg syndrome in patients on dialysis. Drugs 2006; 66: Bone Mineral Density, Vascular Calcifications, and Arterial Stiffness in Peritoneal Dialysis Patients The objective of this study was to evaluate the correlation of bone mineral density (BMD), evaluated by DXA, with vascular calcifications, arterial stiffness, and vascular disease in patients on peritoneal dialysis. Vascular calcifications were evaluated by vascular calcification score on plain x ray, and arterial stiffness was measured by pulse wave velocity using the Complior device (Artech Medical, Pantin, France). Adjusting for multiple factors, lower BMD at the femoral neck, but not at the lumbar spine, was associated with higher pulse wave velocity (p = 0.037), higher vascular calcification score (p = 0.013), and peripheral artery disease (p = 0.006). These data reinforce the hypothesis of the existence of a link between bone disease and cardiovascular disease in dialysis patients. Perit Dial Int 2008; 28: KEY WORDS: Bone mineral density; vascular calcifications; arterial stiffness. In dialysis patients there is increasing evidence of the existence of a link between bone disease and cardiovascular disease. Low bone mineral density (BMD) in the general population is associated with atherosclerotic calcifications (1). The relationship between BMD values and vascular calcifications is one of the issues recommended for clinical research by the imaging work group of the KDIGO International Controversies Conference (2). The objective of this study was to evaluate, in a group of
2 PDI NOVEMBER 2008 VOL. 28, NO. 6 SHORT REPORTS peritoneal dialysis patients, the relationship of BMD with vascular calcifications, pulse pressure, pulse wave velocity (PWV), and cardiovascular disease. PATIENTS This study was a cross-sectional analysis of a cohort of peritoneal dialysis patients. Seventy patients (37 males, 33 females) without previous parathyroidectomy were evaluated after signing an informed consent form. Mean age was 52 ± 14 years and mean dialysis duration was 46 ± 28 months; 17 patients were diabetic. During the 6 months preceding BMD evaluation, 29 and 33 patients were treated, respectively, with calcium carbonate (1.2 ± 0.45 g/day) and calcitriol (1.6 ± 1.2 µg/ week). During this period, dialysate calcium concentrations of 1.25 and 1.75 mmol/l were used, respectively, in 40 and 30 patients. No patient had been previously treated with bisphosphonates or cinacalcet. Coronary artery disease, peripheral artery disease (PAD), and cerebral vascular disease were diagnosed, respectively, in 20, 18, and 8 patients, based on clinical manifestations and diagnostic tests. METHODS Bone mineral density was evaluated by dual-energy x-ray absorptiometry (DXA) using the Hologic QDR Discovery scanner (Hologic, Bedford, Massachusetts, USA) in the lumbar spine and the femoral neck, using NHANES III as the database reference (3). DXA parameters are not standardized for dialysis patients and we used the WHO cutoff of a T-score > 1 SD, which defines normal BMD. According to the Osteoporosis Work Group (4), a Z-score 1 SD, which is adjusted to age, could be more appropriate to diagnose low BMD in dialysis patients. During the first month after BMD evaluation, vascular calcifications were evaluated on plain x rays of pelvis and hands using a method previously described (5), with the final score ranging from 0 to 8. Arterial stiffness was evaluated by pulse pressure (pulse pressure = systolic blood pressure diastolic blood pressure) and by carotid femoral PWV using a noninvasive automated device (Complior; Artech Medical, Pantin, France). Serum levels of the following biochemical parameters were evaluated every month and time averaged for the 6 months preceding the DXA evaluation: calcium, phosphorus, calcium phosphate product, albumin, alkaline phosphatase, and C-reactive protein. Total intact parathyroid hormone was evaluated every 3 months by immunochemiluminescence using a second-generation assay. Statistical Analysis: Data are presented as frequencies for categorical variables and as mean values with SD for continuous variables. Univariate analysis was performed by independent samples t-test, chi-square, Fisher s exact test, paired-samples t-tests, and Pearson correlation coefficient. The association of DXA parameters with cardiovascular factors was evaluated by linear and logistic regression models adjusting for age, gender, diabetes, and body mass index. Absence of colinearity was checked in all models. Vascular calcification score (VCS) was evaluated as a categorical dependent variable (VCS 3) based on our previous studies showing an association between VCS 3 and higher cardiovascular mortality (5). Statistical analyses were performed using the SPSS system 14.0 (SPSS Inc., Chicago, Illinois, USA). A p value < 0.05 was considered statistically significant. RESULTS Vascular calcifications were present in 43 patients. A T-score 1 SD was observed at the lumbar spine in 39 patients and at the femoral neck in 43 patients. A Z-score 1 SD was present at the lumbar spine in 21 patients and at the femoral neck in 24 patients. In univariate analysis, lower femoral T-score (Table 1) was associated with higher pulse pressure, higher PWV, higher prevalence of vascular calcification, and higher prevalence of PAD. Lower femoral BMD was associated with higher VCS and higher PWV (Figure 1). Lower femoral BMD was also associated with presence of coronary artery disease (0.66 ± 0.15 vs 0.74 ± 0.13 g/cm 2, p = 0.03) and PAD (0.64 ± 0.14 vs 0.75 ± 0.13 g/cm 2, p = 0.006) (Figure 1). Patients with vascular calcifications had a higher lumbar T-score than patients without calcifications ( 1.1 ± 1.5 vs 1.7 ± 1.6 SD, p = 0.02). In multivariate analysis, BMD evaluated at the femoral neck was negatively associated with VCS 3, PAD (Table 2), and PWV (Table 3), adjusting for age, gender, diabetes, and body mass index. In similar models, a lower femoral Z-score, but not T-score, was associated with VCS 3 [odds ratio (OR) = 0.5, p = 0.030] and PAD (OR = 0.44, p = 0.016). DISCUSSION In this group of peritoneal dialysis patients, we have verified that low BMD at the femoral neck, but not at the lumbar spine, is independently associated with VCS on plain x ray and with arterial stiffness. The association of lower bone mineral mass or density with vascular calcifications or PWV has already been demonstrated in nonrenal and dialysis patients (1,6,7) but, for the first 669
3 TABLE 1 Cardiovascular Characteristics According to T-Score All patients T-score in lumbar spine T-score in femoral neck (n=70) > 1 SD (n=31) 1 SD (n=39) > 1 SD (n=27) 1 SD (n=43) PP (mmhg) 57.9± ± ± ± ±18.2 a PWV (m/s) 7.8± ± ± ± ±1.6 a VCS 3 29 (41%) 12 (39%) 17 (44%) 7 (26%) 22 (51%) b PAD 18 (26%) 5 (16%) 13 (3%) 2 (7%) 16 (37%) c PP = pulse pressure; PWV = pulse wave velocity; VCS = vascular calcification score; PAD = peripheral artery disease; SD = standard deviation. a p < 0.05: comparison between groups by t-test. b p < 0.05: comparison between groups by chi-square. c p < 0.01: comparison between groups by Fisher s exact test. Figure 1 Lower bone mineral density (BMD) at femoral neck is associated with higher pulse wave velocity, with more calcifications, and with peripheral artery disease (PAD). time, an association between low BMD and plain x-ray vascular calcifications and vascular disease is shown in dialysis patients. Evaluation of vascular calcifications is now required to classify the mineral and bone disorder seen in chronic kidney disease (2), and plain x ray may be a simple and inexpensive method to do so. One explanation for the association of lower BMD with PWV or vascular disease is their common relationship with vascular calcifications (6,8). The absence of association between lumbar BMD and arterial stiffness or vascular calcifications present in our study has already been described in dialysis patients (7) and may be explained by the presence of vascular calcifications in the aorta possibly contributing to a higher BMD value (7). This can also explain why, in our study, patients with calcifications had a higher lumbar T-score compared with patients without calcifications. The pathogenesis of the association between low BMD parameters and vascular calcifications is not known yet and might be explained by a common etiologic factor. Both hyperparathyroidism and adynamic bone disease may be associated with low bone volume (9) and may also be associated with hyperphosphatemia and hypercalcemia, which are inducers of vascular calcifications (10). Low bone turnover has also been associated with vascular calcifications (11). This study presents, however, some limitations: Vascular score has the advantage of simplicity and low cost but it is a semiquantitative evaluation, and the cross-sectional analysis allows only identification of associations between the variables. In conclusion, in this group of patients, lower values of bone mineral density, evaluated by DXA, at the femoral neck but not at the lumbar spine were associated with more calcifications, arterial stiffness, and peripheral 670
4 PDI NOVEMBER 2008 VOL. 28, NO. 6 SHORT REPORTS TABLE 2 Factors Associated with Vascular Calcifications and Peripheral Artery Disease (PAD) Dependent variable Independent variable B OR 95% CI p Value R 2 VCS 3 a 0.45 Age to Diabetes to Phosphorus to BMD (femoral neck) to PAD b 0.29 Diabetes to Phosphorus to BMD (femoral neck) to VCS = vascular calcification score; BMD = bone mineral density; OR = odds ratio; CI = confidence interval. a Adjusted for gender and body mass index. b Adjusted for age, gender, and body mass index. artery disease. The mechanisms for this association are not yet identified but these findings reinforce the hypothesis of the existence of a link between bone disease and vascular disease in dialysis patients. TABLE 3 Factors Associated with Pulse Wave Velocity (PWV) Dependent variable Independent variable B 95% CI p Value R 2 PWV a 0.58 Age to 0.09 <0.001 SBP to Ca P to BMD (femoral neck) to SBP = systolic blood pressure; Ca P = calcium phosphate product; BMD = bone mineral density; CI = confidence interval. a Adjusted for gender, diabetes, and body mass index. Teresa Adragao 1 * Patrícia Branco 2 Rita Birne 1 José Dias Curto 3 Edgar de Almeida 2 Mateus Martins Prata 2 Maria Joao Pais 1 Nephrology Department 1 Santa Cruz Hospital, Carnaxide Nephrology Department 2 Santa Maria Hospital ISCTE Business School 3 Lisbon, Portugal * tadragao@netcabo.pt REFERENCES 1. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O Donnel CJ, Wilson PW, et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001; 68: Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women [Published erratum appears in Osteoporos Int 2008; 19:1103 4]. Osteoporos Int 2008; 19: Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, et al. Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. 671
5 Nephrol Dial Transplant 2004; 19: Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007; 49: Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol 2006; 65: Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15:
Association Between the Vascular Calcification and High Turnover Radiographic Bone Changes in Chronic Kidney Disease Patients
SP_021 Association Between the Vascular Calcification and High Turnover Radiographic Bone Changes in Chronic Kidney Disease Patients Virayavanich W, MD Department of Diagnostic and Therapeutic Radiology,
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationCoronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients
Kidney International, Vol. 65 (2004), pp. 1790 1794 Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients ALI A. HAYDAR, ADRIAN COVIC, HELEN COLHOUN, MICHAEL RUBENS,
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationManagement of mineral and bone disorders in renal transplant recipients
Nephrology 22, Suppl. 2 (2017) 65 69 Management of mineral and bone disorders in renal transplant recipients MATTHEW J DAMASIEWICZ 1,3 and PETER R EBELING 2,3,4 Departments of 1 Nephrology, and 2 Endocrinology,
More informationComparison of Fetuin-A, Vitamin D, Monounsaturated Fatty Acid, and Vascular Calcification on Plain Radiography Between Dialysis Modalities
DIALYSIS Comparison of Fetuin-A, Vitamin D, Monounsaturated Fatty Acid, and Vascular Calcification on Plain Radiography Between Dialysis Modalities Hye In Kim, 1 Won Suk An 1, 2 1 Department of Internal
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationTHE FIELD OF mineral metabolism and
SPECIAL REPORT Controversies in Bone and Mineral Metabolism in Chronic Kidney Disease A Bridge to Improving Healthcare Outcomes and Quality of Life Sharon M. Moe, MD, FACP, and Tilman B. Drüeke, MD, FRCP
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationReversal of adynamic bone disease by lowering of dialysate calcium
http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationLong-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Kazunori Nakayama 1, 2, Kazushi Nakao 1, 2, Yuji Takatori 1,
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationAssociation of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients
Nephrol Dial Transplant (2004) 19: 2564 2569 doi:10.1093/ndt/gfh414 Advance Access publication 27 July 2004 Original Article Association of pelvic arterial calcification with arteriovenous thigh graft
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationBone Disease after Kidney Transplantation
Bone Disease after Kidney Transplantation BTS March 2018 Dr Arif Khwaja PhD, FRCP Sheffield Kidney Institute Clinical case 47 year old female FSGS DBD 2007 egfr 25mls/min. Sirolimus, Azathioprine and prednisolone
More informationVascular calcification and cardiovascular function in chronic kidney disease
NDT Advance Access published November 1, 2005 Nephrol Dial Transplant (2005) 1 of 8 doi:10.1093/ndt/gfi236 Original Article Vascular calcification and cardiovascular function in chronic kidney disease
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationSkeletal status in children and adolescents with chronic renal failure before onset of dialysis or on dialysis
Osteoporos Int (2003) 14: 283 288 DOI 10.1007/s00198-002-1335-6 ORIGINAL ARTICLE Skeletal status in children and adolescents with chronic renal failure before onset of dialysis or on dialysis W. Pluskiewicz
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationSetting the standard
SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics
More informationCost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients
original article http://www.kidney-international.org & 2007 International Society of Nephrology Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,500 1.7 M Open access books available International authors and editors Downloads Our
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationPersistent knee pain in a patient with systemic lupus erythematosus
CASE REPORT Port J Nephrol Hypert 2018; 32(4): 374-378 Advance Access publication 31 October 2018 Persistent knee pain in a patient with systemic lupus erythematosus Miguel Bigotte Vieira 1, *, Joana Monteiro
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationWhat Are the Targets in CKD-MBD?
Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationResearch Article FRAX Fracture Risks Are Associated with Coronary Artery Calcification Score
Hindawi Disease Markers Volume 2017, Article ID 1592598, 6 pages https://doi.org/10.1155/2017/1592598 Research Article FRAX Fracture Risks Are Associated with Coronary Artery Calcification Score Tzyy-Ling
More informationMeasurement of vascular calcification using CT fistulograms
Nephrol Dial Transplant (2007) 22: 484 490 doi:10.1093/ndt/gfl621 Advance Access publication 7 November 2006 Original Article Measurement of vascular calcification using CT fistulograms Nigel D. Toussaint
More informationBenefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results
European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais
More informationUltrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism
Ultrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism Poster No.: C-0304 Congress: ECR 2015 Type: Authors: Keywords: DOI:
More informationVascular access calcification predicts mortality in hemodialysis patients
original article http://www.kidney-international.org & 2008 International Society of Nephrology see commentary on page 1505 Vascular access calcification predicts mortality in hemodialysis patients Georg
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationC ardiovascular disease (CVD) and stroke are the main causes of morbidity and
Original Article DOI: 10.22088/cjim.9.4.347 Risk factors associated with aortic calcification in hemodialysis patients Alireza PeyroShabani 1 Mehrdad Nabahati (MD) 2, 3 MohammadAli Saber Sadeghdoust (MD)
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationOriginal Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis
Int J Clin Exp Med 2015;8(2):2031-2037 www.ijcem.com /ISSN:1940-5901/IJCEM0004376 Original Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationBenefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials
Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J.
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationSlowing the Progression of Vascular Calcification in Hemodialysis
Slowing the Progression of Vascular Calcification in Hemodialysis J Am Soc Nephrol 14: S310 S314, 2003 GLENN M. CHERTOW Division of Nephrology, Department of Medicine, University of California San Francisco,
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationOsteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men
Osteoporos Int (1999) 10:265 270 ß 1999 International Osteoporosis Foundation and National Osteoporosis Foundation Osteoporosis International Original Article Bone Mineral Density and Vertebral Fractures
More informationNomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure
801 Original Article Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure Akira YAMASHINA, Hirofumi TOMIYAMA, Tomio ARAI, Yutaka KOJI, Minoru YAMBE, Hiroaki MOTOBE, Zydem
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationCALCIUM BALANCE AND NEGATIVE IMPACT OF CALCIUM LOAD IN PERITONEAL DIALYSIS PATIENTS. Angela Yee-Moon Wang
Page 1 of 8 Peritoneal Dialysis International Peritoneal Dialysis International, inpress doi: 10.3747/pdi.2013.00177 0896-8608/14 $3.00 +.00 Copyright 2014 International Society for Peritoneal Dialysis
More informationPongamorn Bunnag, MD Boonsong Ongphiphadhanakul, MD. Mahidol University
Roles oesof Fetuin-A in Hypertension Pongamorn Bunnag, MD Boonsong Ongphiphadhanakul, MD Ramathibodi Hospital Mahidol University Fetuin-A (Alpha-2-HS-glycoprotein) Multi-functional protein secreted by
More informationDiagnostische Präzision von DXL im Vergleich zu DXA bei pmp Frauen mit Frakturen
Diagnostische Präzision von DXL im Vergleich zu DXA bei pmp Frauen mit Frakturen Christian Muschitz II. Medizinische Abteilung mit Rheumatologie, Osteologie & Gastroenterologie Akademisches Lehrkrankenhaus
More informationAbstract. Introduction. imedpub Journals Sylvia F Edwards, Amelia E B Moore, Ignac Fogelman and Michelle L Frost.
Research Article imedpub Journals www.imedpub.com The Evaluation of Vertebral Fracture Assessment and Pulse Wave Velocity for the Assessment of Abdominal Aortic Calcification by Comparison to Computed
More informationPrevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.
Dedication Preface Acknowledgments Continuing Education An Introduction to Conventions in Densitometry p. 1 Densitometry as a Quantitative Measurement Technique p. 2 Accuracy and Precision p. 2 The Skeleton
More information